Pendant fatty acid imaging agents
The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.
1. The imaging agent represented by the structure 3:
wherein R 3 is H or alkyl;
R 7 is
wherein the wavy line indicates the point of attachment to the rest of the molecule;
R 8 is selected from the group consisting of ═O (oxo), H, OH, alkoxy, or O-alkyl;
m is an integer between 0 and 12 inclusive;
n is an integer between 0 and 12 inclusive;
p is an integer between 0 and 12 inclusive; wherein a stereochemical configuration of a compound represented by 3 may be R or S, at the stereocenters; or a mixture of these configurations;
or a pharmaceutically acceptable salt or amide thereof.
2. The imaging agent of claim 1 , wherein R 8 is ═O (oxo).
3. A composition comprising the imaging agent of claim 1 , wherein the stereochemical configuration of the imaging agent is a R-stereoisomer, and the composition is of more than about 75% isomeric purity.
4. A composition comprising the imaging agent of claim 1 , wherein the stereochemical configuration of the imaging agent is a S-stereoisomer, and the composition is of more than about 75% isomeric purity.
5. The imaging agent represented by the structure 4:
wherein
R 7 is
wherein the wavy line indicates the point of attachment to the rest of the molecule;
R 8 is selected from the group consisting of ═O (oxo), H, OH, alkoxy, or O-alkyl;
m is an integer selected from 0 to 12;
p is an integer selected from 0, 1, 2, 4, 6 or 8, wherein a stereochemical configuration of a compound represented by structure 4 may be R or S, at the stereocenters; or a mixture of these configurations;
or a pharmaceutically acceptable salt or amide thereof.
6. The imaging agent of claim 5 , wherein m is selected from 0, 1, or 2.
7. A composition comprising the imaging agent of claim 5 , wherein the stereochemical configuration of the imaging agent is a R-stereoisomer, and the composition is of more than about 75% isomeric purity.
8. A composition comprising the imaging agent of claim 6 , wherein the stereochemical configuration of the imaging agent is a S-stercoisomer, and the composition is of more than about 75% isomeric purity.